Clinical Trial Update: Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study [Phase 2]

View source ↗

Summary

A Phase 2 trial of Valiloxybate (XW10172 MR) for Parkinson disease with Excessive Daytime Somnolence has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Valiloxybate (XW10172 MR)

Snippet

Sponsor: XWPharma | Conditions: Parkinson Disease, Excessive Daytime Somnolence | Phase 2 | Status: WITHDRAWN